New biological agents in the treatment of multiple sclerosis

Bratislava Medical Journal

article

M. Buc¹ 

[1]Institute of Immunology, Comenius University Faculty of Medicine

关键词: multiple sclerosis;    neuromyelitis optica;    monoclonal antibodies;    migration of T and B cells;    JC virus;    PML;    IRIS;   

DOI  :  10.4149/BLL_2018_035

学科分类：医学（综合）

来源: AEPress, s.r.o.

【 摘 要 】

Multiple sclerosis (MS) is an inflammatory disease induced by autoimmune processes. Their understanding has resulted in an introduction of biological agents to its treatment. Interferon beta and glatiramer acetate have been in clinical practice for more than 20 years. Nowadays, novel biologics, which target molecules involved in immunopathological processes more specifically have entered the scene. They are represented by monoclonal antibodies binding to molecules VLA4 (natalizumab), CD20 (ocrelizumab), CD52 (alemtuzumab) or alpha subunit of IL-2 receptor (daclizumab) or by small molecules such as those modulating the receptors involved in regulation of lymphocyte migration (fingolimod, ozanimod) or in induction of lymphopenia by apoptosis (dimethyl fumarate, cladribine). In the article, we shortly describe their efficacies, adverse reactions and perspectives of a future development in MS biologics. A treatment of neuromyelitis optica by monoclonal antibodies (rituximab, aquaporumab) is given too (Tab. 1, Fig. 2, Ref. 71).

【 授权许可】

CC BY